Steph & Co. Boosts Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Steph & Co. lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 333 shares of the company’s stock after acquiring an additional 38 shares during the period. Steph & Co.’s holdings in IDEXX Laboratories were worth $180,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Valley National Advisers Inc. increased its position in shares of IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after purchasing an additional 22 shares during the last quarter. DSM Capital Partners LLC acquired a new position in IDEXX Laboratories in the 4th quarter valued at about $33,000. Private Wealth Management Group LLC acquired a new position in IDEXX Laboratories in the 4th quarter valued at about $34,000. Venturi Wealth Management LLC grew its position in IDEXX Laboratories by 226.3% in the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after acquiring an additional 43 shares in the last quarter. Finally, Geo Capital Gestora de Recursos Ltd acquired a new position in IDEXX Laboratories in the 3rd quarter valued at about $28,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In related news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the transaction, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.18% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

IDXX has been the subject of several research reports. Barclays dropped their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Morgan Stanley decreased their price objective on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, June 14th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $586.63.

IDEXX Laboratories Trading Down 0.9 %

NASDAQ:IDXX opened at $491.49 on Tuesday. The firm has a market cap of $40.59 billion, a P/E ratio of 47.58, a PEG ratio of 4.04 and a beta of 1.33. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. The stock’s 50 day simple moving average is $500.81 and its 200-day simple moving average is $528.07. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The business had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.